FDA committee to review Qnexa
MOUNTAIN VIEW, Calif. A Food and Drug Administration committee will review a drug by Vivus for obesity, the drug maker announced Friday.
The company said the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee was tentatively scheduled to review its application for Qnexa (phentermine and topiramate) on July 15. Vivus submitted its approval application for the drug in late December and expects the FDA to complete its review in October.
“Review by the advisory committee represents a critical milestone for Qnexa and for Vivus,” Vivus CEO Leland Wilson said in a statement. “We believe Qnexa, if approved, could become a treatment option for obese patients.”